5 Key Takeaways

• 1

  Migaldendranib is a hydroxyl dendrimer linked to a VEGF receptor TKI, administered as a monthly subcutaneous injection.

• 2

  In early phase 2 trials, migaldendranib showed an approximately 80% reduction in intravitreal injection burden for DME and nAMD.

• 3

  Patients treated with migaldendranib experienced vision improvement of 5 to 6 letters in DME and AMD.

• 4

  The treatment also stabilized the fellow eye, reducing its injection burden by nearly 90%.

• 5

  A phase 2b trial for DME is planned, as initial results showed no progression of diabetic retinopathy in treated patients.